对急性心肌梗死进行溶栓后介入治疗的临床干预疗效评析被引量：2

Evaluation of therapeutic effect of interventional therapy in patients with acute myocardial infarction after thrombolysis

下载PDF

导出

摘要目的:评析对急性心肌梗死进行溶栓后介入治疗的临床干预疗效。方法:收治急性心肌梗死患者186例,分两组,各93例,对照组单纯给予PCI临床干预,观察组先实施静脉溶栓,而后实施择期PCI。对比两组的冠脉再通率、支架植入成功率、死亡率、并发症发生率。结果:观察组PCI后冠脉再通率显著优于对照组(P<0.05)。结论:对急性心肌梗死进行溶栓后行PCI介入治疗可显著提升冠脉再通率,改善患者的临床预后。 Objective:To analyze the clinical intervention effect of interventional therapy on acute myocardial infarction afterthrombolysis.Methods:186 patients with acute myocardial infarction were selected.They were divided into two groups,each of 93cases.The control group was given PCI clinical intervention.The observation group received intravenous thrombolysis first,then theimplementation of elective PCI.We compared the two groups of coronary recanalization rate,success rate of stent implantation,mortality,complication rate.Results:The coronary artery recanalization rate of the observation group was significantly better thanthat of the control group(P<0.05).Conclusion:PCI intervention can significantly improve the coronary reperfusion rate andimprove the prognosis of patients with acute myocardial infarction after thrombolytic therapy.

作者苗秀兰左溢华 Miao Xiulan;Zuo Yihua(Department of Internal Medicine-Cardiovascular,the General Hospital of Jilin Chemical Group Company 132021)

机构地区吉化集团公司总医院心血管内科

出处《中国社区医师》 2016年第16期15-16,共2页 Chinese Community Doctors

关键词急性心肌梗死瑞替普酶 PCI Acute myocardial infarction Reteplase PCI

分类号 R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献4

1陈强,李楠,黄晨,朱家庭,吴友华,马林,徐宝华.尿激酶、阿替普酶与瑞替普酶溶栓治疗肺栓塞对比研究[J].中国民康医学,2013,25(22):47-47. 被引量：16
2张谷,陈玲,林晖.溶栓后PCI和直接性PCI对急性心肌梗死患者的影响分析[J].中国医学创新,2015,12(17):30-32. 被引量：7
3陈泽芳,陈宋璋,王晓群.溶栓后介入治疗和直接PCI治疗急性心肌梗死的疗效和安全性探讨[J].血栓与止血学,2015,21(2):80-82. 被引量：15
4叶世华,魏振华,黄洁莲,杨继俊,陈怡,梁宇,刘志伟,王琼儿,单文,刘建.静脉溶栓治疗急性心肌梗死临床分析[J].中国现代药物应用,2012,6(8):71-72. 被引量：11

二级参考文献37

1蒋世亮,季晓平,张运.美国心脏病学会和美国心脏病协会发布关于ST段抬高型急性心肌梗死治疗指南(2004年修订版)[J].中华医学杂志,2005,85(1):62-64. 被引量：88
2迟建伟林淑娜姜丽丽.急性心肌梗死溶栓治疗相对禁忌证的静脉溶栓治疗[J].中国临床医学研究杂志,2006,12(10):1328-1329.
3Torbicki A,Perrier A, Konstantinides S, et al. Guidelines on he di- agnosis and management of acute pulmonary embolism;the Task Force for the Diagnosis and Management of Acute Pulmonary Em- bolism of the European Society of Cardiology(ESC) [ J]. Eur Heart J,2008,29:2276 -2315.
4Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein throm- bosis, and chronic thromboembolic pulmonary hypertension: a sci- entific atatement from the American Heart Association Criculation, 2011.123,1788 - 1830.
5Le Cal C, Righini M, Roy PM, et al. Prediction of pulmonary embo- liism in the emergency department:the revised Ceneva score [ J ]. Ann Intern Med,2006,144 ( 3 ) : 165 - 171.
6Pollack CV, Schreiber D, Coldhaber SC, et al. Clinical characteris- ties,managemnt and out - comes of patients diagnosed with acute pulmonary embolism in the emergency Department:initial report of EMPEROR( Muhicenter Emergency Medicine Pulmonary Embolism in the Real Word Registry)[J]. J Am Coil Cardiol,2011,57(6) : 700 - 706.
7Laporte S, Mismetti P, Decousus H, et a|. Clinical predictors for fa- tal pulmonary embolism in 1520 patients with venous thromboembo- lism: findings from the Registro informatizado de la enfermedad Tromboembolica Venosa Registry [ J ]. Circulation, 2008,117 ( 13 ) : 1711 -1716.
8Lankeit M, Konstantinides S. Thmmbolysis for pulmonary embolism past, present and future[ J ]. Thromb Haemost, 2010,103 ( 5 ) : 877 -883.
9Brilakis ES, Reeder GS, Gersh BJ. Modem management of acute myocardial infarction [ J ]. Curt Probl Cardio1,2003,28 ( 1 ) : 1117 - 1125.
10ZHAO ZQ, CORVERA JS, HALKES ME, et al. Inhibition of myocardial injury by ischemic postconditiening during reper- fusion:comparison with ischemie preconditioning ~ J]. Am J Physiol Heart Circ Physiol,2003,285 :H579-H588.